The Inhibitory Effect on Tumor Cells Proliferation Induced by Arsenic Through DNMTs and its Downstream Molecules: A Systematic Review and Meta-Analysis

Author:

Li Shugang1ORCID,Zhang Jingyi2ORCID,Li Sheng2,Ma Mingxiao2

Affiliation:

1. Department of Maternal and Children Health, School of Public Health, Capital Medical University, Beijing 100069, China

2. Department of Public Health, School of Medicine, Shihezi University, Shihezi 832000, Xinjiang, China

Abstract

Background: We aimed to systematically evaluate the regulatory effect of arsenic on DNMTs and its downstream molecules in tumor cells, and to provide a theoretical basis for revealing the specific mechanism of arsenic in the treatment of tumors Methods: Meta-analysis was performed using RevMan 5.3 and Stata 12.0, and differences between groups were described as standard mean differences Results: We found out that compared with the control group, the expression of DNMT1, DNMT3a, DNMT3b, MMP-9 & β-catenin decreased and the expression of RECK and E-cadherin increased in arsenic-treated group. Subgroup analysis showed that high-dose arsenic exposure (> 2 μmol/L) reduced the expression of DNMT1, DNMT3b, MMP-9, and β-catenin and promoted the expression of E-cadherin. Arsenic could decrease the level of DNMT1, MMP-9 & β-catenin and increase the level of E-cadherin with short-time arsenic intervention (≤ 48 h). Arsenic could reduce DNMT1, DNMT3a, DNMT3b & β-catenin in hematological tumor cells; under the effect of arsenic, the expression of DNMT1, DNMT3b, MMP-9 & β-catenin were decreased in solid tumor cells. In addition, the regulation of arsenic on DNMT3a was dose-dependent in the range of arsenic concentration from 0 to 5.0 μmol/L. The dose, time, and cell types of arsenic intervention were the sources of heterogeneity Conclusion: Arsenic could inhibit the proliferation and viability of tumor cells, and its mechanism may be related to the reduction of DNMTs and regulation of the expression of its downstream molecules. Overall, arsenic may be a possible candidate for the treatment of tumors.

Funder

National Natural Science Foundation of China

Publisher

Bentham Science Publishers Ltd.

Subject

Drug Discovery,Pharmacology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3